ZA200204859B - Method of decreasing fasting sugars and weight gains in diabetic patients. - Google Patents

Method of decreasing fasting sugars and weight gains in diabetic patients.

Info

Publication number
ZA200204859B
ZA200204859B ZA200204859A ZA200204859A ZA200204859B ZA 200204859 B ZA200204859 B ZA 200204859B ZA 200204859 A ZA200204859 A ZA 200204859A ZA 200204859 A ZA200204859 A ZA 200204859A ZA 200204859 B ZA200204859 B ZA 200204859B
Authority
ZA
South Africa
Prior art keywords
diabetic patients
weight gains
decreasing fasting
sugars
fasting sugars
Prior art date
Application number
ZA200204859A
Other languages
English (en)
Inventor
Landschulz William Harras
Original Assignee
Pfitzer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfitzer Products Inc filed Critical Pfitzer Products Inc
Publication of ZA200204859B publication Critical patent/ZA200204859B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA200204859A 2001-06-21 2002-06-18 Method of decreasing fasting sugars and weight gains in diabetic patients. ZA200204859B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30004901P 2001-06-21 2001-06-21

Publications (1)

Publication Number Publication Date
ZA200204859B true ZA200204859B (en) 2004-01-28

Family

ID=23157477

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200204859A ZA200204859B (en) 2001-06-21 2002-06-18 Method of decreasing fasting sugars and weight gains in diabetic patients.

Country Status (15)

Country Link
US (2) US20030079747A1 (OSRAM)
EP (1) EP1270012A1 (OSRAM)
JP (1) JP2003012543A (OSRAM)
KR (1) KR20020097033A (OSRAM)
CN (1) CN1289143C (OSRAM)
AU (1) AU4884102A (OSRAM)
CA (1) CA2390757A1 (OSRAM)
CZ (1) CZ20022151A3 (OSRAM)
HK (1) HK1049617B (OSRAM)
HU (1) HUP0202042A3 (OSRAM)
IL (1) IL150209A0 (OSRAM)
NZ (1) NZ519403A (OSRAM)
PL (1) PL354641A1 (OSRAM)
SK (1) SK9042002A3 (OSRAM)
ZA (1) ZA200204859B (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004054606A1 (en) * 2002-12-13 2004-07-01 Pfizer Products Inc. Method of decreasing hepatic glucose output in diabetic patients
PT1454630E (pt) * 2003-03-04 2010-12-15 Technology Dev Company Ltd Composição de insulina injectável de acção prolongada e métodos para o seu fabrico e utilização
EP1973523A2 (en) * 2005-12-15 2008-10-01 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
WO2008118387A2 (en) * 2007-03-23 2008-10-02 Wayne State University Erythrocyte atp-release modulators
EP2060268A1 (en) * 2007-11-15 2009-05-20 Novo Nordisk A/S Pharmaceutical compositions for pulmonary or nasal delivery of peptides
ES2517268T3 (es) * 2009-07-22 2014-11-03 Eli Lilly And Company Procedimiento para predecir el aumento de peso asociado a una terapia farmacéutica

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5230884A (en) * 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
DK10191D0 (da) * 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
CA2444415A1 (en) * 1991-07-02 1993-01-21 Nektar Therapeutics Method and device for delivering aerosolized medicaments
US5320094A (en) * 1992-01-10 1994-06-14 The Johns Hopkins University Method of administering insulin
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5785049A (en) * 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
US5743250A (en) * 1993-01-29 1998-04-28 Aradigm Corporation Insulin delivery enhanced by coached breathing
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
DK0748213T3 (da) * 1994-03-07 2004-08-02 Nektar Therapeutics Fremgangsmåder og sammensætninger til pulmonal indgivelse af insulin
RU2146153C1 (ru) * 1994-09-21 2000-03-10 Инхейл Терапьютик Системз Устройство и способ распыления лекарственных средств в виде сухого порошка (варианты)
US5898028A (en) * 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
DE19733651A1 (de) * 1997-08-04 1999-02-18 Boehringer Ingelheim Pharma Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole
ES2177323T3 (es) * 1998-10-16 2002-12-01 Novo Nordisk As Preparaciones de insulina concentradas estables para la administracionpor via pulmonar.
EP1173482A1 (en) * 1999-04-27 2002-01-23 Eli Lilly And Company Insulin crystals for pulmonary administration
AU5453300A (en) * 1999-06-29 2001-01-31 Eli Lilly And Company Insulin crystals for pulmonary administration
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
ATE442148T1 (de) * 2001-04-04 2009-09-15 Ortho Mcneil Janssen Pharm Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren
IL158862A0 (en) * 2001-05-21 2004-05-12 Nektar Therapeutics An insulin composition for pulmonary administration

Also Published As

Publication number Publication date
CZ20022151A3 (cs) 2003-04-16
CN1289143C (zh) 2006-12-13
HUP0202042A2 (hu) 2004-05-28
US20050220722A1 (en) 2005-10-06
AU4884102A (en) 2003-01-02
HK1049617B (zh) 2007-03-16
SK9042002A3 (en) 2003-05-02
IL150209A0 (en) 2002-12-01
HK1049617A1 (en) 2003-05-23
EP1270012A1 (en) 2003-01-02
KR20020097033A (ko) 2002-12-31
HUP0202042A3 (en) 2004-06-28
CA2390757A1 (en) 2002-12-21
JP2003012543A (ja) 2003-01-15
NZ519403A (en) 2005-03-24
CN1393265A (zh) 2003-01-29
US20030079747A1 (en) 2003-05-01
PL354641A1 (en) 2002-12-30
HU0202042D0 (OSRAM) 2002-08-28

Similar Documents

Publication Publication Date Title
AU2001282550A1 (en) Method of quantifying total hemoglobin and glycohemoglobin
GB2385280B (en) Gaming system and gaming method
AU2003230813A1 (en) Online league and tournament system
AU2001298042A1 (en) Optimized pulsatile-flow ventricular-assist device and total artificial heart
AU2003248675A1 (en) Gaming system and method
IL164400A0 (en) Deruvatuves if n-Äphenyl(piperidin-2-yl)methylÜbenzamide, the preparation method thereof and application of same in therapeutics
AU2002310076A1 (en) Structure and method to preserve sti during etching
AU2003245026A1 (en) Multipurpose processor, system and method
AU2001276952A1 (en) Method of treating the syndrome of coronary heart disease risk factors in humans
AU2003214775A1 (en) Physiologically compatible cardiac assist device and method
GB0110288D0 (en) Composition and treatment method
PL354191A1 (en) Laminated material, application thereof and method of obtaining same
AU2003214725A1 (en) Preventing and/or treating cardiovascular disease and/or associated heart failure
AU2002367023A1 (en) Compositions and methods for treating heart failure
AU2002351206A1 (en) Lateral lubistor structure and method
AU2002349237A1 (en) Coring system and method
AU2002365057A1 (en) Compositions and methods for treating heart failure
ZA200204859B (en) Method of decreasing fasting sugars and weight gains in diabetic patients.
AU2003224956A1 (en) Reference structures and reference structure enhanced tomography
AU2002366813A1 (en) Cardiac pacing method and system
AU2002316162A1 (en) Method of increasing anti-neugc antibody levels in blood
AU1907901A (en) Sandwich construction and method for its manufacture
AU2003278754A1 (en) Motocycle lift bar and method
AU2001275959A1 (en) Method of treating the syndrome of type 2 diabetes in humans
AU2003228787A1 (en) Composition and method for reducing post-prandial blood glucose